Search

Our evaluations of mpox diagnostics

There remains limited information about the performance of mpox diagnostics, particularly those suitable for decentralized settings closer to communities.

From 2022 to 2024, we have been conducting diagnostic evaluation studies in collaboration with multiple independent sites to determine the accuracy of mpox diagnostics.   

An initial expression of interest was launched in 2022 for the first round of evaluations, with a new round of selection launched in 2024 for a second round. 

Evaluation protocol 2022 (1st round)

Performance evaluation of Mpox point-of-care diagnostics Protocol Version Number: 2.0 Date: 25 May 2023

CompanyAssayEvaluation resultsCountry of manufacturerTest typeReader/
platform
Evaluation status
AconFlowflex Monkeypox Virus Antigen Rapid TestSee resultsChinaAntigen RDTn/a1st round completed in:
- DRC
- UK
Assure
Biotech
Monkeypox Virus Antigen Rapid TestSee resultsChinaAntigen RDTn/a1st round completed in:
- DRC
- UK
SD BiosensorSTANDARD Q MpoxSee resultsRepublic of KoreaAntigen RDTn/a1st round completed in:
- DRC
- UK
SD BiosensorSTANDARD M10 MPX/OPXSee resultsRepublic of KoreaPOC molecularM10 platform1st round completed in:
- DRC
- UK
CepheidXpert MpoxSee resultsUnited StatesPOC molecularGeneXpert1st round completed in:
- DRC
- UK